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EXECTUTIVE SUMMARY 
 
Abstract: The purpose of this study was to determine if a preoperative dose of celecoxib and 
pregabalin in patients who underwent total hip arthroplasty (THA) or total knee arthroplasty 
(TKA) was associated with less opioid consumption intraoperatively and postoperatively 
compared to those who did not receive this regimen.  
Introduction: THA and TKA have been associated with a high incidence of postoperative pain. 
Historically, this pain has been managed with opioids; however, these drugs have negative side 
effects associated with their use. Consequently, anesthesia providers have begun utilizing 
multimodal non-opioid analgesics. Recently, a specific combination has been utilized, which 
includes a nonsteroidal anti-inflammatory drug known as celecoxib (Celebrex) and an 
anticonvulsant known as pregabalin (Lyrica). While this combination may be a beneficial 
alternative for opioids, there is no consensus on the timeliness or effectiveness of a single 
combination dose of these drugs at alleviating perioperative pain. 
Methodology: A retrospective cross-sectional study design was utilized for this study that 
included 200 patients who underwent THA or TKA between May 1, 2008 and May 1, 2018 at 
Charleston Area Medical Center. A total of 100 patients were included in group one, which 
consisted of patients who did not receive a preoperative dose of celecoxib and pregabalin or any 
other preoperative analgesics. Group two consisted of 100 patients who did receive a 
preoperative dose of both celecoxib and pregabalin. The primary independent variable was the 
preoperative administration of celecoxib and pregabalin. Secondary independent variables 
consisted of gender, age, body mass index (BMI), and American Society of Anesthesiologists 
(ASA) physical classification scores. The dependent variables consisted of intraoperative opioid 
consumption and total opioid consumption in the postoperative anesthesia care unit (PACU). 
Control variables consisted of gender, age, BMI and ASA physical classification scores. The 
research hypotheses were that patient who underwent THA or TKA and received preoperative 
doses of both celecoxib and pregabalin would have less opioid consumption in the intraoperative 
period and less opioid consumption in the PACU, compared to those who did not receive the 
same combination preoperatively. 
Results:  Comparison of the two groups yielded no differences between mean age, BMI or 
gender. The mean age and ASA classification between the two groups were statistically 
different, p=.0001 and p=.017. Group one consisted of 55 females and 45 males, while group 
two consisted of 52 females and 48 males. The study also revealed there was a statistical 
significance in terms of PACU opioid consumption (p=.001) between the two groups but no 
statistical difference in intraoperative opioid consumption (p>.05). Group one received a mean 
difference of approximately 1.2 morphine equivalents more than group two. There was no 
statistical significance between PACU opioid consumption and age, gender, BMI, or ASA 
classification. Analysis showed there was a statistical association between intraoperative opioid 
consumption and age (p=.022) and gender (p=.025). Further analysis revealed females received a 
mean of 3.22 morphine equivalents more than males.  
Discussion:  The study results supported the hypothesis that preoperative celecoxib and 
pregabalin would be associated with a decrease in PACU opioid consumption in patients 
undergoing THA or TKA. These results did not support the additional study hypothesis that this 
combination would also decrease intraoperative opioid consumption. 
Implications and Recommendations: The results of this study supported the use of 
preoperative celecoxib and pregabalin at reducing PACU opioid consumption. Additional 
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prospective, randomized studies are needed to compare the use of celecoxib and pregabalin 
independently versus in combination. 
Conclusion: In conclusion, this study found an association between the preoperative 
administration of celecoxib and pregabalin in patients undergoing THA or TKA and decreased 
PACU opioid consumption; however, no association was found between the preoperative 
administration of celecoxib and pregabalin and decreased intraoperative opioid consumption in 
these patients.   
Key Words: Arthroplasty, celecoxib, opioid, pregabalin, pain 
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INTRODUCTION 
Background and Significance of the Problem 
Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are surgical procedures 
in which damaged cartilage and bone are removed from the hip or knee area and replaced with 
prosthetic components (American Academy of Orthopaedic Surgeons, 2015a, 2015b). According 
to a 2010 report from the National Center for Health Statistics, TKA is the most commonly 
performed inpatient surgery on patients aged 45 years and older with an approximate 693,400 
being performed annually (Williams, Woldford, & Bercovitz, 2015).  This number has been 
predicted to increase to 3.48 million per year by 2030 (Kurtz, Ong, Lau, Mowat, & Halpern, 
2007). In comparison, THA surgeries have been predicted to increase from 326,100 annually to 
526,000 by 2030 (Kurtz et al., 2007; Woldford, Palso, & Bercovitz, 2015). 
The primary indication for THA or TKA is a chronic pain disease known as 
osteoarthritis, which affects more than 30 million adults in the United States (Centers for Disease 
Control and Prevention [CDC], 2017; National Institutes of Health, 1994). Osteoarthritis is a 
chronic pain disease that causes cartilage to breakdown in bones and joints that leads to stiffness 
and edema (CDC, 2017). While people suffering from osteoarthritis undergo total joint 
arthroplasty to relieve these symptoms, this type of surgery often leads to chronic postoperative 
pain (Peterson & Arendt-Nielson, 2016). This chronic pain can lead to prolonged recovery, 
increased morbidity, chronic opioid use, and increased health care costs (Gan, 2017). Therefore, 
managing pain during this period for patients undergoing THA or TKA has remained a challenge 
for anesthesia providers. In the past, opioids have been the mainstay of pain management in 
these procedures; however, opioids have adverse effects associated with their use such as 
constipation, nausea and vomiting, respiratory depression, tolerance, and physical dependence 
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(Benayamin et al., 2008; Golladay, Balch, Dalury, Satpathy, & Jiranek, 2017). To decrease the 
negative side effects associated with opioids, surgeons and anesthesia providers have begun 
utilizing multimodal analgesic techniques that include both opioid and non-opioid analgesics 
(Halawi, Grant, & Bolognesi, 2015). These non-opioid analgesics have included local 
anesthetics, anticonvulsants such as pregabalin and gabapentin, and nonsteroidal anti-
inflammatory drugs (NSAID) such as acetaminophen, ketorolac and celecoxib (Halawi et al., 
2015). While some studies have shown that multimodal analgesic techniques can be effective in 
managing postoperative pain, other studies have indicated that these techniques have 
demonstrated no superiority to opioids and may actually increase opioid consumption, healthcare 
costs, and postoperative delirium (Brooks, Freter, Bowles, & Amirault, 2017; Halawi et al., 
2015). 
Many non-opioid analgesics have not been formulated for intravenous use; therefore, 
they are administered orally and preoperatively and are considered preemptive analgesics. 
Preemptive analgesics are pain relieving treatments that are administered before surgical incision 
that continue to exert their effects throughout the procedure to the initial postoperative period 
(Kissin, 2000). Preemptive analgesics inhibit central sensitization, which is an altered response 
to pain that intensifies postoperative pain (Kissin, 2000). Preventing central sensitization can 
decrease chronic pain, which has been reported to be 12.4% of patients who undergo THA or 
TKA. (Golladay et al., 2017; Nikolajsen, Brandsborg, Lucht, Jensen, & Kehlet, 2006).  
A specific preemptive non-opioid combination that has been utilized during THA and 
TKA surgeries is celecoxib and pregabalin (Carmichael et al., 2013). Although specific studies 
have not been conducted to demonstrate if synergistic effects exist between pregabalin and 
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celecoxib, studies have indicated that when pregabalin is combined with other NSAIDs, such as 
naproxen, a synergistic relationship exists (Hurley, Chatterjea, Rose Feng, Taylor, & Hammond, 
2002). Analgesic drugs are believed to be synergistic if they exhibit a greater pain-relieving 
effect when used in combination than when either drug is used alone.  
Literature Review 
NSAIDs  such as celecoxib have been used around the world to treat pain and 
inflammation for over 100 years (Vane, 2000). NSAIDs demonstrate their effects by inhibiting 
the prostaglandin producing catalytic enzyme prostaglandin H2 synthase (PGHS), also known as 
cyclooxygenase (COX) (Vane, 1971). There are two types of cyclooxygenase enzymes: 
cyclooxygenase type 1 (COX-1) and cyclooxygenase type 2 (COX-2) (Seibert et al., 1994). 
COX-1 enzymes participate in physiological hemostasis and maintain the integrity of the 
gastrointestinal and renal system, while COX-2 enzymes are inducible enzymes that are only 
present at sites of inflammation (Vane, Bakhle, & Botting, 1998).     
Pharmacologic agents that interfere with these enzymes have been known to decrease 
pain and inflammation and are referred to as cyclooxygenase inhibitors (Vane et al., 1998). 
These drugs work by selectively inhibiting either COX-1 or COX-2, or simultaneously inhibiting 
both enzymes (Vane et al., 1998). The nonselective forms of these drugs, such as aspirin, 
naproxen, and ibuprofen have been used to treat pain associated with the inflammation process, 
but these drugs exhibit other side effects such as decreased platelet functioning and increased 
gastrointestinal toxicity (Vane et al., 1998). 
While nonselective COX inhibiting drugs have proven to be beneficial for specific types 
of patients, such as those suffering with thrombotic disorders, their use in the perioperative area 
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can lead unwanted side effects such as increased blood loss during surgery (Connelly & Panush, 
1991). These unwanted side effects have limited the use of nonselective NSAIDs in the 
perioperative period. Consequently, most NSAIDs are stopped days or even weeks before 
surgery; however, because a selective cyclooxygenase inhibitor such as celecoxib only 
demonstrates its effects on COX-2 enzymes it does not interfere with normal platelet function 
(Teerawattananon, Tantayakom, Suwanawiboon, & Katchamart, 2017). Therefore, it does not 
increase the risk of intraoperative bleeding (Teerawattananon et al., 2017). These beneficial 
pharmacologic properties have led to an increased use of celecoxib in the perioperative period; 
however, celecoxib must be administered orally three hours before surgical incision in order to 
be effective in treating pain (Pfizer INC, 2015). 
Currently, celecoxib is the only Food and Drug Administration (FDA) approved selective 
NSAID available in the United States. Previous COX-2 selective inhibitors such as valdecoxib 
and rofecoxib have been removed from the market due to an increased risk of adverse 
cardiovascular effects with their use (U.S Food & Drug Administration, 2018). In order to 
remain on the market the FDA ordered the manufacturer to complete a cardiovascular safety 
trial, which is now known as the Prospective Safety Versus Ibuprofen or Naproxen 
(PRECISION) trial (Nissen et al., 2016). The authors concluded that celecoxib had less risk of 
gastrointestinal side effects than naproxen and less renal side effects than ibuprofen. The authors 
also suggested that moderate doses of celecoxib were not associated with an increased risk of 
cardiovascular events when compared to nonselective NSAIDs such as naproxen and ibuprofen. 
Due to the findings of this study, as of today, celecoxib remains on the market in the United 
States for the treatment of pain. 
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The FDA approved pregabalin 2004 for the treatment of peripheral neuropathy, 
neuralgia, and seizures. Since then, it has also been approved for the treatment of a chronic pain 
illness known as fibromyalgia and neuropathic pain (Pfizer Pharmaceuticals LLC, 2011). While 
pregabalin is a structural analog of the inhibitory neurotransmitter known gamma-aminobutyric 
acid (GABA), it does not exert its action at GABA receptor sites (Pfizer Pharmaceuticals LLC, 
2011). Instead, the drug binds to voltage-gated calcium channel receptors in the central nervous 
system and decreases the release of neurotransmitters that signal pain (Pfizer Pharmaceuticals 
LLC, 2011). Although this mechanism of action is not fully understood, it is believed that 
pregabalin interferes with the pain transmission pathway from the brainstem to the spinal cord 
that is involved in the formation of  chronic pain (Pfizer Pharmaceuticals LLC, 2011). 
Various studies have been performed to determine the effectiveness of celecoxib and/or 
pregabalin during total joint arthroplasty, but most focus on the long-term effectiveness of both 
preoperative and repeated postoperative doses of these drugs. In 2015, a prospective randomized 
control trial that consisted of a total of 64 participants who underwent THA showed that patients 
who received a preoperative 400 milligram (mg) dose of celecoxib and additional scheduled 200 
mg doses of celecoxib every 12 hours had decreased pain scores at 12, 24, 48, and 72 hours after 
surgery (Chen et al., 2015). Additionally, the treatment group had decreased opioid consumption 
at 6, 12, and 24 hours postoperatively compared to the control group. While the treatment group 
consisted of both preoperative and postoperative doses of celecoxib, decreased opioid 
consumption at 6 hours in the treatment group suggested that a single preoperative dose of 
celecoxib may have been effective in alleviating pain in the immediate postoperative period 
because repeated doses were not administered until 12 hours after surgery. Additionally, the 
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incidence of postoperative nausea and vomiting was lower in the treatment group (Chen et al., 
2015). 
In 2012, a randomized double-blind placebo study that consisted of ninety patients 
undergoing distal extremity surgery compared the effectiveness of a single preoperative dose of 
200 mg of celecoxib versus 320 mg of acetaminophen (Kashefi, Honarmand, & Safavi, 2012). 
The authors of this study showed that pain scores four hours postoperatively were significantly 
lower in the celecoxib group compared to the acetaminophen and placebo group. Additionally, 
this study found that there were no statistically significant differences in pain scores in the three 
groups four hours after surgery.  
In 2015, a prospective, randomized controlled trial that included 120 participants 
evaluated postoperative pain in patients undergoing TKA (YaDeau et al., 2015). Authors 
discovered that patients who had received preoperative and postoperative doses of pregabalin in 
addition to an NSAID did not have decreased pain or opioid consumption compared to those 
who received the same regimen without pregabalin. The authors also revealed that patients in the 
pregabalin group had increased sedation on postoperative day one. 
In 2011, a randomized placebo-controlled trial that consisted of 50 participants 
undergoing discectomy showed that the treatment group who received a single 150 mg dose of 
pregabalin had reduced preoperative anxiety and postoperative pain (Spreng, Dahl, & Raeder, 
2011). Although pain scores and morphine consumption did not differ significantly 24 hours 
postoperatively between the two groups, the authors did reveal that patients in the pregabalin 
group were able to be discharged from the post anesthesia care unit (PACU) earlier and had 
significantly lower pains scores at 120 minutes postoperatively. A similar double-blind 
randomized controlled trial in 2011, that consisted of 32 patients, demonstrated that a single 300 
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mg dose of pregabalin did not reduce pain intensity in patients undergoing discectomy; however, 
compared to the placebo, the pregabalin group did have decreased morphine consumption. 
(Hegarty & Shorten, 2011).  
A 2015, a double-blind, randomized, placebo-controlled study that consisted of 184 
participants showed that patients undergoing THA, who received a preoperative and 
postoperative combination of celecoxib and pregabalin, had less morphine consumption 12, 24, 
and 48 hours postoperative compared to the placebo group who received the same anesthetic 
regimen without pregabalin (Clarke et al., 2015). The authors also discovered that pain scores 
were lower 1-7 days after discharge. Another randomized controlled trial conducted in 2012 that 
consisted of 60 participants compared the analgesic effectiveness of preoperative celecoxib 
versus pregabalin during open cholecystectomy procedures (Ali & Babar, 2012). The authors 
concluded that neither drug was superior because there were no significant differences in 
postoperative pain scores, opioid consumption, or incidence postoperative nausea and vomiting 
between the two treatment groups (Ali & Babar, 2012). It was also noted in the study that the 
pregabalin group had a higher frequency of sedation. 
Statement of the Problem and Research Purpose 
Due to the predicted increase in total joint arthroplasties previously mentioned, the 
increasing age of the patient population undergoing THA and TKA, and the deleterious side 
effects of opioids, it is essential for surgeons and anesthesia providers to continue investigating 
the efficacy of multimodal pain management. While the use of preemptive multimodal 
combinations such as pregabalin and celecoxib in THA and TKA has been explored, there is no 
consensus on the effectiveness of single combination doses or the timeliness of this specific drug 
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combination at alleviating pain in the immediate postoperative period, therefore; further studies 
are warranted. The purpose of this study was to determine if a preoperative dose of celecoxib and 
pregabalin in patients who underwent THA or TKA was associated with less opioid consumption 
intraoperatively and postoperatively compared to those who did not receive this regimen. The 
importance of this study was to evaluate if orally administered non-opioid analgesics 
combinations such as these are an effective tool for anesthesia providers to utilize in the 
perioperative period.  The findings of this study could lead to improved evidence based clinical 
practices and enhanced patient outcomes at Charleston Area Medical Center (CAMC) in 
Charleston, West Virginia and other facilities that perform THA or TKA.  
METHODOLOGY 
Research Hypotheses 
The specific aim of this study was to evaluate the effectiveness of preemptive non-opioid 
analgesics in THA and TKA. The main objective of this study was to evaluate the effectiveness 
of preoperative celecoxib and pregabalin administration at reducing intraoperative and 
postoperative opioid consumption. There were two proposed hypotheses for this study. The 
hypotheses were: 
1. Patients who underwent THA or TKA and received preoperative doses of both celecoxib 
and pregabalin will have less opioid consumption in the intraoperative period compared 
to those who did not receive the same combination preoperatively. 
2. Patients who underwent THA or TKA and received preoperative doses of both celecoxib 
and pregabalin will have less opioid consumption in the PACU compared to those who 
did not receive the same combination preoperatively. 
Research Design/Setting 
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The study design chosen was a retrospective cross-sectional design. This type of study 
design allowed for rapid cost efficient data collection for the intended patient population 
(Jacobsen, 2017). Data was collected from medical records at CAMC in Charleston, WV. 
CAMC is a non-profit hospital that is made up of 965 beds (Charleston Area Medical Center 
[CAMC], 2018). CAMC is made up of four divisions: CAMC General Hospital, CAMC 
Memorial Hospital, CAMC Women and Children’s Hospital and CAMC Teays Valley Hospital 
(CAMC, 2018).  
Sample Population and Description of Sample 
A retrospective chart review was performed on patients who underwent elective THA or 
TKA between May 1, 2008 and May 1, 2018 at CAMC. The sample population was divided into 
two groups for comparison. Group one consisted of 100 patients who underwent THA or TKA 
that did not receive both celecoxib and pregabalin preoperatively or any other preoperative 
analgesics. Group two consisted of 100 patients who underwent THA or TKA that did receive 
pregabalin and celecoxib. 
The sample was identified using codes for THA and TKA surgeries from both the 
International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) and 
International Classification of Diseases 10th revision Procedure Coding System (ICD-10-PCS). 
The ICD-9-CM code for THA is 81.52. The ICD-9-CM code for TKA is 81.54. ICD-10 PCS 
codes for THA and TKA are listed in Appendix C. 
Inclusion criteria: 
1. Adult male or female 18 years of age or older 
2. Patients who had an American Society of Anesthesiologist (ASA) physical 
classification I-IV 
  
   10
3. Patients who underwent THA or TKA 
4. Patients who received both celecoxib and pregabalin preoperatively 
Exclusion criteria: 
1. Patients less than 18 years old 
2. Patients with allergies to celecoxib or pregabalin 
3. Patients who underwent emergent or traumatic THA or TKA 
4. Patients who received opioids preoperatively 
5. Patients who received spinal anesthesia 
6. Patients who received pregabalin or celecoxib in a single dose preoperative and not in 
combination 
7. Patient who received any other analgesics preoperatively 
8. Patients who had an American Society of Anesthesiologist (ASA) physical 
classification V or VI 
Procedures/Protocol 
A retrospective chart review was performed on patients who underwent elective THA or 
TKA between May 1, 2008 and May 1, 2018 at CAMC. A sample size of 200 patients was 
utilized. Patient demographics and clinical information were collected and included: age, gender, 
body mass index (BMI), ASA classification, the preoperative administration of both celecoxib 
and pregabalin or lack of, intraoperative opioid consumption, and total opioid consumption while 
in the PACU. These variables were collected from the Electronic Medical Record (EMR), 
Medication Administration Record (MAR), PACU record and intraoperative anesthesia record. 
The primary independent variable was the preoperative administration of a combination of 
celecoxib and pregabalin. Secondary independent variables consisted of gender, age, BMI, and 
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ASA physical class scores. The dependent variables were total intraoperative and opioid 
consumption while in the PACU.  
Patient age was calculated on day of surgery. Patient gender was defined as male or 
female. BMI was determined by extracting patients’ height in centimeters (cm) and weight in 
kilograms (kg). BMI was calculated by dividing the patients weight in kg by their height squared 
in meters (CDC, 2018). ASA physical classification scores were collected, which is a grading 
tool used by anesthesia providers to classify a patient’s health status. Class I includes healthy 
patients with no comorbities, Class II includes patients with mild systemic disease, Class III 
includes patients with severe noncapactitiating systemic disease, Class IV includes patients with 
incapacitiating systemic disease that threatens life, Class V is reserved for patients that are not 
expected to live without surgery, and Class VI consists of organ donating patients have been 
declared brain dead (American Society of Anesthesiologists, 2014). Opioid consumption was 
recorded from the EMR and anesthesia record and converted to morphine equivalents to permit a 
standard comparison among various opioids.  
Data Collection and Instrumentation 
Data was extracted from each patient’s EMR and organized using a Microsoft Excel 
spreadsheet. The EMR for each patient was accessed and data was extracted from the MAR, 
preoperative evaluation, intraoperative anesthesia record, and PACU record. An anonymous 
number was assigned to each patient in Data Collection Tool 1 (Appendix A) to maintain 
confidentiality. Data Collection Tool 2 (Appendix B) was utilized to organize data that was 
collected and included age, gender, ASA classification, weight, BMI, celecoxib and pregabalin 
administration or the lack thereof, total intraoperative opioid consumption and total opioid 
consumption in the PACU. 
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Statistical Design and Analysis 
The main purpose of this study was to determine if there was an association between a 
preoperative dose of celecoxib and pregabalin and decreased perioperative opioid consumption 
in patients who underwent THA or TKA. The primary independent variable was the preoperative 
administration of celecoxib and pregabalin. Secondary independent variables consisted of 
gender, age, BMI, and ASA physical class scores. The dependent variables consisted of 
intraoperative and PACU opioid consumption. Independent t-tests were performed to compare if 
statistical differences existed between age and BMI in the two groups. A chi-squared test was 
performed to determine if a statistical difference existed between gender and ASA between the 
two groups. Two step-wise linear regression was used to predict a statistical association between 
celecoxib and pregabalin administration, age, BMI, gender, ASA classification with 
intraoperative opioid consumption and opioid consumption in PACU. IBM SPSS statistical 
software was utilized to analyze data. A p-value of <.05 was considered statistically significant.  
Ethical Considerations 
 This study was approved by the CAMC/West Virginia University Internal Review Board 
on June 12, 2018 (Appendix D). 
RESULTS 
Presentation, Analysis, and Interpretation of the Data 
The study sample consisted of 200 patients aged 40-90 years of age who underwent THA 
or TKA at CAMC. The sample was divided into two groups.  Group one consisted of 100 
patients who underwent THA or TKA and did not receive celecoxib and pregabalin 
preoperatively or any other preoperative analgesics. Group two consisted of 100 patients who 
underwent THA or TKA and received a preoperative combination of celecoxib and pregabalin.  
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Independent t-tests were used to compare differences in mean age and BMI between the 
two groups. Mean BMI between the two group was not significantly different (p=>.05). The 
mean age difference between the two groups was statistically different p=.0001. The mean age 
for group one was 66.50 ± 9.8 years and the mean age for group two was 59.27 ± 8.6 years. 
Mean BMI for group one was 33.59 ± 7.09 (kg/m2) and for group two was 32.68 ± 5.9 (kg/m2). 
Chi-squared test was performed to compare gender and recoded ASA classification between the 
two groups. Gender between the two groups was not statistically different, (p>.05). Group one 
consisted of 55 females and 45 males, while group two consisted of 52 females and 48 males A 
significant difference existed between the two groups in terms of ASA classification p=.017 
(p<.05). Group one had 20 ASA class 1-2 patients and 80 ASA class 3-4 patients. Group two had 
35 ASA class 1-2 patients and 65 ASA class 3-4 patients. Each group consisted of 57 patients 
who underwent TKA and 43 patients who underwent THA, (Table 1). 
Table 1: Demographics and Clinical Characteristics of Patients Who Underwent Total Hip or Knee 
Arthroplasty and Comparisons of Age, BMI, Gender, and ASA Class 
 
 
 
 
Variable 
Total Sample Study Groups Statistical 
Value 
 
Total 
N=100 
Mean (SD) 
Did not receive 
celecoxib and 
pregabalin 
N=100 (50%) 
Mean (SD) 
Received 
celecoxib and 
pregabalin 
N=100 (50%) 
Mean  (SD) 
 
p-Value 
 
Age (years) 32.7 (9.2) 66.50 (9.8) 59.27 (8.6) .0001* 
BMI (kg/m2) 33.12 (3.0) 33.59 (7.09) 32.68 (5.90) (NS) 
Gender (F/M) (N) 
Female 
 
Male 
 
F = 107 
 
M = 93 
 
F = 55 
 
M =45 
 
F = 52 
 
M = 48 
(NS) 
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*Indicated significant value (p<.05), NS=Not Significant (p>.05), SD=Standard Deviation, 
BMI=Body Mass Index, ASA=American Society of Anesthesiologist physical status 
classification, F=female, M=male. 
There was no statistical significance between the two groups when comparing mean 
intraoperative opioid consumption, (p>.05).  Mean intraoperative opioid consumption was 22.56 
± 10.6 morphine equivalents for group 1 and 22.81 ± 9.8 morphine equivalents for group 2. A 
comparison of the two groups showed statistical significance between the two groups in mean 
PACU opioid consumption, p=.001. Group one received a mean of 3.59 ± 3.65 morphine 
equivalents and group two received a mean of 2.15 ± 2.56 morphine equivalents, (Table 2). 
Table 2: Comparison of Intraoperative and PACU Opioid Consumption Between Group One and 
Group Two 
 
 
 
Variable 
 
Total Sample Study Groups Statistical Value 
 
Total Sample 
N=100 
Mean (SD) 
 
Did not receive 
celecoxib and 
pregabalin 
N=100 (50%) 
Mean (SD) 
 
Received 
celecoxib and 
pregabalin 
N=100 (50%) 
Mean  (SD) 
 
p-Value 
 
Intraoperative 
opioid 
administration 
(morphine 
equivalents) 
 
23.2 (10.2) 
 
22.8 (9.8) 23.6 (10.6) (NS) 
PACU opioid 
administration 
(morphine 
equivalents) 
 
2.9 (2.6) 
 
3.6 (3.7) 2.2 (2.6) .001* 
 
ASA 1-2 N (%) 
 
ASA 3-4 N (%) 
 
 
 
55 (27.5%) 
 
145 (72.5%) 
 
 
 
 
20 (20%)  
 
80 (80%) 
 
 
      35 (35%) 
 
65 (65%) 
.018* 
THA 
 
TKA 
 
114 (57%) 
 
86 (43%) 
57 (57%) 
 
43 (43%) 
57 (57%) 
 
43 (43%) 
NS 
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* Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation, 
PACU = post-anesthesia care unit. 
Linear regression was used to identify statistical association between mean intraoperative 
opioid consumption and the following independent variables: age, gender, BMI, recoded ASA 
class, and the preoperative administration of celecoxib and pregabalin or lack thereof. There was 
no statistical significance between mean intraoperative opioid consumption and BMI, ASA, or 
celecoxib/pregabalin administration or the lack thereof (p>.05). There was a statistical 
significance between intraoperative opioid consumption when considering age (p=.022) and 
gender (p=.025), (Table 3). 
Table 3: Linear Regression Analysis Between Age, BMI, ASA, Celecoxib and Pregabalin Use, 
and Intraoperative Opioid Consumption in Patients Undergoing Total Hip or Knee Arthroplasty 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 31.723 7.394  4.291 .0001 
Age* -.184 .080 -.179 -2.302 .022* 
Gender:* 3.199 1.414 .157 2.263 .025* 
BMI .114 .113 .073 1.004 .317 
ASA -2.403 1.617 -.106 -1.486 .139 
Celecoxib and 
Pregabalin         -9.32 1.529 -0.46 -.610 .543 
*Indicated significant value (p<.05), NS=Not Significant (p>.05), SD=Standard Deviation, 
BMI=Body Mass Index, ASA=American Society of Anesthesiologist physical status 
classification, F=female, M=male, Y=yes N=no. 
Linear regression was used to identify statistical association between PACU opioid 
consumption and the following independent variables: age, gender, BMI, recoded ASA class, 
and the preoperative administration of celecoxib and pregabalin or lack thereof. There was no 
statistical association between PACU opioid consumption and age, gender, ASA, and BMI. 
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There was a statistical significance between PACU opioid consumption and the administration of 
celecoxib or pregabalin or the lack thereof p=.002, (Table 4). 
Table 4: Linear Regression Analysis Between Age, BMI, ASA, Celecoxib and Pregabalin Use, 
and PACU Opioid Consumption in Patients Undergoing Total Hip or Knee Arthroplasty 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 3.325 2.355  1.412 .160 
Age -.020 .025 -.061 -.780 .437 
Gender:  .713 .450 .110 1.583 .115 
BMI .023 .036 .046 .637 .525 
ASA .622 .515 .086 1.207 .229 
Celebrex and 
Pregabalin          -1.499 .487 -.232 -3.079 .002* 
*Indicated significant value (p<.05), NS=Not Significant (p>.05), SD=Standard Deviation, 
BMI=Body Mass Index, ASA=American Society of Anesthesiologist physical status 
classification, F=female, M=male, Y=yes N=no. 
An independent t-test was used to compare gender with intraoperative and PACU 
opioids. There was no statistical association between total PACU opioids and gender. There was 
a statistical significance between total intraoperative opioids and gender (p=.21), (Table 5). 
Table 5: Independent t-test Comparing Gender and Intraoperative and PACU Opioid 
Consumption  
 
 
t-test for Equality of Means 
df Sig. (2-tailed) 
Mean 
Difference 
Total Intraoperative 
Opioids* 
Equal variances assumed 198 .21* 3.3102 
Equal variances not 
assumed 194.592 .19 3.3102 
Total PACU Opioids Equal variances assumed 198 .588 .2494 
Equal variances not 
assumed 189.183 .578 .2494 
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* Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation, 
PACU = post-anesthesia care unit 
An independent t-test was conducted to assess if there was a statistical significance 
between males or females. In terms of intraoperative opioids, females received a mean 21.68 ± 
10.14 morphine equivalents and males received a mean 24.92 ± 9.98 morphine equivalents. 
These finding were statistically significant p<.05, (Table 6). 
Table 6: Independent T-Test Comparing Gender and Intraoperative Opioid Consumption in 
Patients Undergoing TKA or THA 
 Gender: M=1, F = 0 N Mean Std. Deviation 
Intraoperative Opioids 
(morphine equivalents) 
F 107 21.68 10.1359 
M 93 24.920 9.9768 
* Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation, 
F=female, M=Male. 
 Independent t-tests were conducted to determine if there was a statistical significance 
between type of surgery (THA or TKA) and age. Mean age for patients undergoing TKA in the 
study was 63.96 ± 8.208 and for THA was 61.45 ± 11. 621.There was no statistical significance 
between type of surgery and age (p>.05), (Table 7). 
Table 7: Independent T-Test Comparing Type of Surgery (TKA or THA) and Age  
 Surgery: TKA/THA N Mean Std. Deviation Sig. (2-tailed) 
Age (years) TKA 114 63.96 8.208 .075 
THA 86 61.45 11.621 .075 
Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation, 
TKA=total knee arthroplasty, THA=total hip arthroplasty. 
 Further analysis was performed to determine if there was a statistical association between 
type of surgery and gender. There were 65 females and 49 males in the TKA group. There was 
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42 females and 44 males in the THA group. There was no statistical association between gender 
and type of surgery (p>.05), (Table 8). 
Table 8: Chi-Square Test Comparing Type of Surgery (TKA or THA) and Gender 
 Gender: F or M TKA  THA Total Sig. (2-tailed) 
 F 65 42 107 .251 
M 49 44 93 .251 
Indicated significant value (p<.05), NS=Not significant (p>.05), SD=Standard Deviation, 
TKA=total knee arthroplasty, THA=total hip arthroplasty.  
DISCUSSION 
Discussion of Study Results 
The purpose of this study was to determine if an association could be made between a 
preoperative dose of celecoxib and pregabalin in patients undergoing THA or TKA and their 
intraoperative and PACU opioid consumption. The hypotheses predicted that patients who 
received a preoperative dose of both celecoxib and pregabalin would consume less opioids 
intraoperatively and postoperatively. The study revealed there was a statistical significance in 
terms of PACU opioid consumption between the two groups but no statistical difference in 
intraoperative opioid consumption. The group that did not receive celecoxib and pregabalin 
preoperatively (group one) received a mean difference of approximately 1.2 morphine 
equivalents more than group two. 
Independent t-tests and chi-squared tests revealed that mean BMI and gender between the 
two groups was not statistically significantly different; however, ASA classification and age 
were statistically significantly different between the two groups.  Group one, that did not receive 
celecoxib and pregabalin, had more patients with ASA 3-4 classifications and were older by a 
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mean of approximately 7 years. Therefore, based on previous research on this topic, it would be 
anticipated that group one would have required less opioids due to the mean age of this group 
being greater (Kanonidou & Karystianou, 2007). However, the results of this study showed that 
there was an increased amount of opioid consumption in group one which had older aged 
patients. This could be also be attributed to the increased number of ASA 3-4 class patients in 
this group. Further research is needed to determine if there are associations between higher ASA 
classifications and opioid consumption. 
Independent t-tests showed that there was a statistical significance between intraoperative 
opioid consumption and age and gender. Further, independent t-tests revealed that females 
received less opioids intraoperatively, approximately 21.68 morphine equivalents compared to 
males receiving 24.9 morphine equivalents. This study is consistent with findings from a 2003 
study in which the authors revealed that females are more sensitive than males to the effects of 
opioids; therefore, they require a lesser amount (Pleym, Spigset, Kharasch, & Dale, 2003). 
Further analysis was conducted to examine the association between age and both 
intraoperative and PACU opioid consumption. Patients were assigned to two groups. Group A 
consisted of patients aged 40-64 years and group B consisted of patients aged 65-90 years. The 
analysis showed there was no statistical difference between the groups in terms of PACU opioid 
consumption. The analysis showed that the older aged group (group B) received approximately 
3.3 morphine equivalents less than group A. The older aged group (group B) received a mean of 
21.42 ± 11.22 morphine equivalents and the younger aged group (group A) received 24.725 ± 
11.22 morphine equivalents. These results are in consensus with the previous research mentioned 
that found a decreased opioid need in older aged patients (Kanonidou & Karystianou, 2007). 
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A 2015 study revealed that patients who underwent THA were approximately 65 years 
old and those who underwent TKA were approximately 67 years old (Fang, Noiseux, Linson, & 
Cram, 2015). Additional analysis was conducted to determine if there was a statistical 
association between the type of surgery (TKA or THA) and age in the current study. The mean 
age for patients undergoing TKA in this study was 63.96 ± 8.208 and for THA was 61.45 ± 11. 
621. While the results of the current study do not concur with the results of the previously 
mentioned study, there was no statistical significance between the two groups in terms of age and 
types of surgery (p>.05). There was also no significant association between type of surgery 
(THA or TKA) and gender, (p>0.05). 
Study Limitations 
There were numerous limitations to this research. Most influentially was the retrospective 
nature of the study which did not allow for total control of the variables. Retrospective cross-
sectional studies have less control of variables than prospective studies; consequently, this type 
of study could not prove causation only association.  
Numerous cofounding variables could have affected the results such as the administration 
of NSAIDs as well as the use of local anesthetics. The author was unable to control these 
variables or convert the doses of those medications into morphine equivalents. Another variable 
that may have affected the results is the type of surgery since both THA and TKA were included 
to allow for a larger sample size. Differences in personnel such as surgeons, anesthesia 
providers, and nursing staff may have influenced the total opioid consumption. Additionally, 
variations in charting between anesthesia providers and nursing staff could have affected the 
study. Additional prospective studies are needed in the future to compare the use of celecoxib 
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and pregabalin when administrated separately compared to when used in combination dose in 
total joint replacement surgery. 
IMPLICATIONS AND RECOMMENDATIONS 
The results of this study supported the use of preoperative celecoxib and pregabalin at 
reducing PACU opioid consumption. In the future, additional prospective, randomized studies 
are needed to compare the use of celecoxib and pregabalin independently versus in combination. 
In these studies, variables such as specific type of joint replacement surgery and perioperative 
administration of an NSAID and any local anesthetic use must be controlled. 
CONCLUSION 
In conclusion, this study found an association between the preoperative administration of 
celecoxib and pregabalin in patients undergoing THA or TKA and decreased PACU opioid 
consumption; however, no association was found between the preoperative administration of 
celecoxib and pregabalin and decreased intraoperative opioid consumption. The results of this 
study can improve patient outcomes in patients undergoing TKA or THA at CAMC or similar 
facilities where these procedures are performed. 
 
 
 
 
  
   22
 
References 
 
Ali, A., & Babar, K. M. (2012). Comparision of preoperative dose of pregabalin with celecoxib 
for attentuation of postoperative pain after open cholecystectomy. Anaesthesia Pain & 
Intensive Care, 16(2), 137-141.  
American Academy of Orthopaedic Surgeons. (2015a, August 2015). Total hip replacement. 
Retrieved from https://orthoinfo.aaos.org/en/treatment/total-hip-replacement/ 
American Academy of Orthopaedic Surgeons. (2015b, August 2015). Total knee replacement. 
           Retrieved from https://orthoinfo.aaos.org/en/treatment/total-knee-replacement/ 
American Society of Anesthesiologists. (2014). ASA physical classification system. Retrieved 
from https://www.asahq.org/resources/clinical-information/asa-physical-status-
classification-system 
Benayamin, R., Trescot, A. M., Datta, S., Buenaventura, R., Adlaka, R., Sehgal, N., . . . Vallejo, 
R. (2008). Opioid complications and side effects. Pain Physician 2008: Opioid Special 
Issue, 11, S105-S120.  
Brooks, E., Freter, S. H., Bowles, S. K., & Amirault, D. (2017). Multimodal pain management in 
older elective arthroplasty patients. Geriatric Orthopaedic Surgery & Rehabilitation, 
8(3), 151-154. doi:10.1177/2151458517720297 
Carmichael, N. M., Katz, J., Clarke, H., Kennedy, D., Kreder, H. J., Gollish, J., & McCartney, C. 
J. (2013). An intensive perioperative regimen of pregabalin and celecoxib reduces pain 
and improves physical function scores six weeks after total hip arthroplasty: a prospective 
randomized controlled trial. Pain Res Manag, 18(3), 127-132.  
Centers for Disease Control and Prevention [CDC]. (2017). What is osteoarthritis (OA)? 
Retrieved from https://www.cdc.gov/arthritis/basics/osteoarthritis.htm 
  
   23
Centers for Disease Control and Prevention [CDC]. (2018). Body Mass Index. Retrieved  
              August 14, 2018 from http://www.cdc.gov/healthyweight/assessing/bmi/ 
Charleston Area Medical Center [CAMC]. (2018). CAMC Hospital & Centers. 
Retrieved August 14, 2018 from http://camc.org/hospitals-centers 
Chen, J., Zhu, W., Zhang, Z., Zhu, L., Zhang, W., & Du, Y. (2015). Efficacy of celecoxib for 
acute pain management following total hip arthroplasty in elderly patients: A prospective, 
randomized, placebo-control trial. Experimental and Therapeutic Medicine, 10, 737-742.  
Clarke, H., Page, G. M., McCartney, C. J., Huang, A., Stratford, P., Andrion, J., . . . Katz, J. 
(2015). Pregabalin reduces postoperative opioid consumption and pain for 1 week after 
hospital discharge, but does not affect function at 6 weeks or 3 months after total hip 
arthroplasty. British Journal of Anaesthesia, 115(6), 903-911. doi:10.1093/bja/aev363 
Connelly, C. S., & Panush, R. S. (1991). Should nonsteroidal anti-inflammatory drugs be 
stopped before elective surgery? Archives Intenalr Medicine, 151, 1963-1966.  
Fang, M., Noiseux, N., Linson, E., & Cram, P. (2015). The effect of advancing age on total 
            joint replacement outcomes. Geriatric Orthopaedic Surgery & Rehabilitation, 6(3),  
           173-179. doi:10.1177/2151458515583515  
Gan, T. J. (2017). Poorly controlled postoperative pain: prevalence, consequences, and 
prevention. Journal Pain Research, 10, 2287-2298. doi:10.2147/JPR.S144066 
Golladay, G. J., Balch, K. R., Dalury, D. F., Satpathy, J., & Jiranek, W. A. (2017). Oral 
multimodal analgesia for total joint arthroplasty. The Journal of Arthroplasty, 3 (9s), 
 269-73. doi:10.1016/j.arth.2017.05.002 
Halawi, M. J., Grant, S. A., & Bolognesi, M. P. (2015). Multimodal analgesia for total joint 
arthroplasty. Orthopedics, 38(7), e616-e625. doi:10.3928/01477447-20150701-61 
  
   24
Hegarty, D. A., & Shorten, G. D. (2011). A randomised, placebo-controlled trial of the effects of 
preoperative pregabalin on pain intensity and opioid consumption following lumbar 
discectomy. The Korean Journal of Pain, 24(1), 22-30. doi:10.3344/kjp.2011.24.1.22 
Hurley, R. W., Chatterjea, D., Rose Feng, M., Taylor, C. P., & Hammond, D. L. (2002). 
Gabapentin and pregabalin can interact synergistically with naproxen to produce 
antihyperalgesia. Anesthesiology, 97(5), 1263-1273.  
Jacobsen, K. H. (2017). Introduction to health research methods: a practical guide (2nd ed.). 
Burlington, MA: Jones & Barnett Learning. 
Kanonidou, Z., & Karystianou, G. (2007). Anesthesia for the elderly. Hippokratia Quarterly 
Medical Journal, 11(4), 175-177.  
Kashefi, P., Honarmand, A., & Safavi, M. (2012). Effects of preemptive analgesia with celecoxib 
or acetaminophen on postoperative pain relief following lower extremity orthopedic 
surgery. Advanced Biomedical Research, 1(4), 1-5. doi:10.4103/2277-9175.100197 
Kissin, I. (2000). Preemptive analgesia. Anesthesiology, 93(4), 1134-1164.  
Kurtz, S., Ong, K., Lau, E., Mowat, F., & Halpern, M. (2007). Projections of primary and 
revision hip and knee arthroplasty in the United States from 2005 to 2030. Journal of 
Bone Joint Surgery, 89(4), 780-785. doi:10.2106/JBJS.F.00222 
National Institutes of Health. (1994). NIH consesus statement: total hip arthroplasty.  Retrieved 
from https://consensus.nih.gov/1994/1994HipReplacement098PDF.pdf. 
Nikolajsen, L., Brandsborg, B., Lucht, U., Jensen, T. S., & Kehlet, H. (2006). Chronic pain 
following total hip arthroplasty: a nationwide questionnaire study. Acta 
Anaesthesiologica Scandinavica, 50(4), 495-500. doi:10.1111/j.1399-6576.2006.00976.x 
  
   25
Nissen, S. E., Yeomans, N. D., Solomon, D. H., Luscher, T. F., Libby, P., Husuni, E., . . . 
Lincoff, A. (2016). Cardiovascular safety of celecoxib, naproxen, iburprofen from 
arthritis. The New England Journal of Medicine, 375(26), 2519-2529. 
doi:10.1056/NEJMoa1611593 
Peterson, K. K., & Arendt-Nielson, L. (2016). Chronic postoperative pain after joint 
replacement. International Society for the Study of Pain, 24(3), 1-6.  
Pfizer INC. (2015). Celebrex. New York, NY: Pfizer. 
Pfizer Pharmaceuticals LLC. (2011). Highlights of prescribing information. New York, NY: 
Parke-Davis. 
Pleym, H., Spigset, O., Kharasch, E. D., & Dale, O. (2003). Gender differences in drug effects: 
implications for anesthesiologists. Acta Anaesthesiolica Scandinavica, 47(3), 241-259.  
Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., . . . Isakson, P. (1994). 
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in 
inflammation and pain. Proceeding of the National Academy of Sciences USA, 91(25), 
12013-12017.  
Spreng, U. J., Dahl, V., & Raeder, J. (2011). Effect of a single dose of pregabalin on post-
operative pain and pre-operative anxiety in patients undergoing discectomy. Acta 
Anaesthesiolica Scandivavica, 55(5), 571-576. doi:10.1111/j.1399-6576.2011.02410.x 
Teerawattananon, C., Tantayakom, P., Suwanawiboon, B., & Katchamart, W. (2017). Risk of 
perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A 
systematic review and meta-analysis. Seminars Arthritis Rheumatism, 46(4), 520-528. 
doi:10.1016/j.semarthrit.2016.07.008 
  
   26
U.S Food & Drug Administration. (2018). Vioxx (rofecoxib) Questions. Cox-2 selective 
(includes bextra, celebrex, and vioxx) and non-selective non-steroidal anti-inflammatory 
drugs (NSAIDS). Retrieved from 
https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandpro
viders/ucm429364.htm 
Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-
like drugs. Nature New Biology, 231(25), 232-235.  
Vane, J. R. (2000). The fight against rheumatism: from willow bark to cox-1 sparing drugs. 
Journal of Phyisiology and Pharmacology, 51(4), 573-586.  
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998). Cyclooxygenases 1 and 2. Annual Review of 
Pharmacology and Toxicology, 38(1).  97-120.  
Williams, S. N., Woldford, M. L., & Bercovitz, A. (2015). NCHS data data brief: 
Hospitalization for total knee replacement among inpatients aged 45 and over: United 
States, 2000-2010. Hyattsville, MD: National Center for Health Statistics Retrieved from 
https://www.cdc.gov/nchs/data/databriefs/db210.pdf. 
Woldford, M. L., Palso, K., & Bercovitz, A. (2015). NCHS data data brief: Hospitalization for 
total hip replacement among inpatients aged 45 and over: United States, 2000-2010. 
Hyattsville, MD: National Center for Health Statistics Retrieved from 
https://www.cdc.gov/nchs/data/databriefs/db186.pdf. 
YaDeau, J. T., Lin, Y., Mayman, D. J., Goytizolo, E. A., Alexiades, M. M., Padgett, D. E., . . . 
Westrich, G. H. (2015). Pregabalin and pain after total knee arthroplasty: a double-blind, 
randomized, placebo-controlled, multidose trial. British Journal Anaesthesia, 115(2), 
285-293. doi:10.1093/bja/aev217 
  
   27
 
APPENDICES 
 
Appendix A: Data Collection Tool 1  
Patient Safety Number Patient Identification Number 
1  
2  
3  
4  
5  
…  
200  
Appendix B: Data Collection Tool 2  
Study 
# 
Age 
(years) 
Gender 
(Male=1 
Female=0) 
ASA 
(I-IV) 
Weight 
(kg) 
BMI 
(kg/m2) 
Celecoxib 
and 
Pregabalin 
(Y=1, N=0) 
Total 
Intraoperative 
Opioids 
(morphine 
equivalents) 
Total PACU 
Opioids (morphine 
equivalents) 
1         
2         
3         
4         
5         
…         
200         
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Appendix C: ICD-10-PCS THA and TKA CODES 
 
Code Procedure 
0SRB Replacement of Left Hip Joint 
0SRB0 Replacement of Left Hip Joint, Open 
Approach 
0SRB019 Replacement of Left Hip Joint with Metal 
Synthetic Substitute, Cemented, Open 
Approach 
0SRB01A Replacement of Left Hip Joint with Metal 
Synthetic Substitute, Uncemented, Open 
Approach 
0SRB01Z Replacement of Left Hip Joint with Metal 
Synthetic Substitute, Open Approach 
0SRB029 Replacement of Left Hip Joint with Metal on 
Polyethylene Synthetic Substitute, Cemented, 
Open Approach 
0SRB02A Replacement of Left Hip Joint with Metal on 
Polyethylene Synthetic Substitute, 
Uncemented, Open Approach 
0SRB02Z Replacement of Left Hip Joint with Metal on 
Polyethylene Synthetic Substitute, Open 
Approach 
0SRB039 Replacement of Left Hip Joint with Ceramic 
Synthetic Substitute, Cemented, Open 
Approach 
0SRB03A Replacement of Left Hip Joint with Ceramic 
Synthetic Substitute, Uncemented, Open 
Approach 
0SRB03Z  Replacement of Left Hip Joint with Ceramic 
Synthetic Substitute, Open Approach 
0SRB049 Replacement of Left Hip Joint with Ceramic 
on Polyethylene Synthetic Substitute, 
Cemented, Open Approach 
0SRB04A Replacement of Left Hip Joint with Ceramic 
on Polyethylene Synthetic Substitute, 
Uncemented, Open Approach 
0SRB04Z Replacement of Left Hip Joint with Ceramic 
on Polyethylene Synthetic Substitute, Open 
Approach 
0SRB069 Replacement of Left Hip Joint with Oxidized 
Zirconium on Polyethylene Synthetic 
Substitute, Cemented, Open Approach 
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0SRB06A Replacement of Left Hip Joint with Oxidized 
Zirconium on Polyethylene Synthetic 
Substitute, Uncemented, Open Approach 
0SRB06Z Replacement of Left Hip Joint with Oxidized 
Zirconium on Polyethylene Synthetic 
Substitute, Open Approach 
0SRB07Z Replacement of Left Hip Joint with 
Autologous Tissue Substitute, Open 
Approach 
0SRB0J9 Replacement of Left Hip Joint with Synthetic 
Substitute, Cemented, Open Approach 
0SRB0JA Replacement of Left Hip Joint with Synthetic 
Substitute, Uncemented, Open Approach 
0SRB0JZ Replacement of Left Hip Joint with Synthetic 
Substitute, Open Approach 
0SRB0KZ Replacement of Left Hip Joint with 
Nonautologous Tissue Substitute, Open 
Approach 
0SR9 Replacement of Right Hip Joint 
0SR90 Replacement of Right Hip Joint, Open 
Approach 
0SR9019 Replacement of Right Hip Joint with Metal 
Synthetic Substitute, Cemented, Open 
Approach 
0SR901A Replacement of Right Hip Joint with Metal 
Synthetic Substitute, Uncemented, Open 
Approach 
0SR901Z Replacement of Right Hip Joint with Metal 
Synthetic Substitute, Open Approach 
0SR9029 Replacement of Right Hip Joint with Metal on 
Polyethylene Synthetic Substitute, Cemented, 
Open Approach 
0SR902A Replacement of Right Hip Joint with Metal on 
Polyethylene Synthetic Substitute, 
Uncemented, Open Approach 
0SR902Z Replacement of Right Hip Joint with Metal on 
Polyethylene Synthetic Substitute, Open 
Approach 
0SR9039 Replacement of Right Hip Joint with Ceramic 
Synthetic Substitute, Cemented, Open 
Approach 
0SR903A Replacement of Right Hip Joint with Ceramic 
Synthetic Substitute, Uncemented, Open 
Approach 
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0SR903Z Replacement of Right Hip Joint with Ceramic 
Synthetic Substitute, Open Approach 
0SR9049 Replacement of Right Hip Joint with Ceramic 
on Polyethylene Synthetic Substitute, 
Cemented, Open Approach 
0SR904A Replacement of Right Hip Joint with Ceramic 
on Polyethylene Synthetic Substitute, 
Uncemented, Open Approach 
0SR904Z Replacement of Right Hip Joint with Ceramic 
on Polyethylene Synthetic Substitute, Open 
Approach 
0SR9069 Replacement of Right Hip Joint with 
Oxidized Zirconium on Polyethylene 
Synthetic Substitute, Cemented, Open 
Approach 
0SR906A Replacement of Right Hip Joint with 
Oxidized Zirconium on Polyethylene 
Synthetic Substitute, Uncemented, Open 
Approach 
0SR906Z Replacement of Right Hip Joint with 
Oxidized Zirconium on Polyethylene 
Synthetic Substitute, Open Approach 
0SR907Z Replacement of Right Hip Joint with 
Autologous Tissue Substitute, Open 
Approach 
0SR90J9 Replacement of Right Hip Joint with 
Synthetic Substitute, Cemented, Open 
Approach 
0SR90JA Replacement of Right Hip Joint with 
Synthetic Substitute, Uncemented, Open 
Approach 
0SR90JZ Replacement of Right Hip Joint with 
Synthetic Substitute, Open Approach 
0SR90KZ Replacement of Right Hip Joint with 
Nonautologous Tissue Substitute, Open 
Approach 
0SRE Replacement of Left Hip Joint 
0SRE0 Replacement of Left Hip Joint, Open 
Approach 
0SRE009 Replacement of Left Hip Joint, Acetabular 
Surface with Polyethylene Synthetic 
Substitute, Cemented, Open Approach 
0SRE00A Replacement of Left Hip Joint, Acetabular 
Surface with Polyethylene Synthetic 
Substitute, Uncemented, Open Approach 
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0SRE00Z Replacement of Left Hip Joint, Acetabular 
Surface with Polyethylene Synthetic 
Substitute, Open Approach 
0SRE019 Replacement of Left Hip Joint, Acetabular 
Surface with Metal Synthetic Substitute, 
Cemented, Open Approach 
0SRE01A Replacement of Left Hip Joint, Acetabular 
Surface with Metal Synthetic Substitute, 
Uncemented, Open Approach 
0SRE01Z Replacement of Left Hip Joint, Acetabular 
Surface with Metal Synthetic Substitute, Open 
Approach 
0SRE039 Replacement of Left Hip Joint, Acetabular 
Surface with Ceramic Synthetic Substitute, 
Cemented, Open Approach 
0SRE03A Replacement of Left Hip Joint, Acetabular 
Surface with Ceramic Synthetic Substitute, 
Uncemented, Open Approach 
0SRE03Z Replacement of Left Hip Joint, Acetabular 
Surface with Ceramic Synthetic Substitute, 
Open Approach 
0SRE07Z Replacement of Left Hip Joint, Acetabular 
Surface with Autologous Tissue Substitute, 
Open Approach 
0SRE0J9 Replacement of Left Hip Joint, Acetabular 
Surface with Synthetic Substitute, Cemented, 
Open Approach 
0SRE0JA Replacement of Left Hip Joint, Acetabular 
Surface with Synthetic Substitute, 
Uncemented, Open Approach 
0SRE0JZ Replacement of Left Hip Joint, Acetabular 
Surface with Synthetic Substitute, Open 
Approach 
0SRE0KZ Replacement of Left Hip Joint, Acetabular 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
0SRA Replacement of Right Hip Joint 
0SRA0 Replacement of Right Hip Joint, Open 
Approach 
0SRA009 Replacement of Right Hip Joint, Acetabular 
Surface with Polyethylene Synthetic 
Substitute, Cemented, Open Approach 
0SRA00A Replacement of Right Hip Joint, Acetabular 
Surface with Polyethylene Synthetic 
Substitute, Uncemented, Open Approach 
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0SRA00Z Replacement of Right Hip Joint, Acetabular 
Surface with Polyethylene Synthetic 
Substitute, Open Approach 
0SRA019 Replacement of Right Hip Joint, Acetabular 
Surface with Metal Synthetic Substitute, 
Cemented, Open Approach 
0SRA01A Replacement of Right Hip Joint, Acetabular 
Surface with Metal Synthetic Substitute, 
Uncemented, Open Approach 
0SRA01Z Replacement of Right Hip Joint, Acetabular 
Surface with Metal Synthetic Substitute, Open 
Approach 
0SRA039 Replacement of Right Hip Joint, Acetabular 
Surface with Ceramic Synthetic Substitute, 
Cemented, Open Approach 
0SRA03A Replacement of Right Hip Joint, Acetabular 
Surface with Ceramic Synthetic Substitute, 
Uncemented, Open Approach 
0SRA03Z Replacement of Right Hip Joint, Acetabular 
Surface with Ceramic Synthetic Substitute, 
Open Approach 
0SRA07Z Replacement of Right Hip Joint, Acetabular 
Surface with Autologous Tissue Substitute, 
Open Approach 
0SRA0J9 Replacement of Left Hip Joint, Acetabular 
Surface with Synthetic Substitute, Cemented, 
Open Approach 
0SRA0JA Replacement of Right Hip Joint, Acetabular 
Surface with Synthetic Substitute, 
Uncemented, Open Approach 
0SRA0JZ Replacement of Right Hip Joint, Acetabular 
Surface with Synthetic Substitute, Open 
Approach 
0SRA0KZ Replacement of Right Hip Joint, Acetabular 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
0SRS Replacement of Left Hip Joint, Femoral 
Surface 
0SRS0 Replacement of Left Hip Joint, Femoral 
Surface, Open Approach 
0SRS019 Replacement of Left Hip Joint, Femoral 
Surface with Metal Synthetic Substitute, 
Cemented, Open Approach 
0SRS01A Replacement of Left Hip Joint, Femoral 
Surface with Metal Synthetic Substitute, 
Uncemented, Open Approach 
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0SRS01Z Replacement of Left Hip Joint, Femoral 
Surface with Metal Synthetic Substitute, Open 
Approach 
0SRS039 Replacement of Left Hip Joint, Femoral 
Surface with Ceramic Synthetic Substitute, 
Cemented, Open Approach 
0SRS03A Replacement of Left Hip Joint, Femoral 
Surface with Ceramic Synthetic Substitute, 
Uncemented, Open Approach 
0SRS03Z Replacement of Left Hip Joint, Femoral 
Surface with Ceramic Synthetic Substitute, 
Open Approach 
0SRS07Z Replacement of Left Hip Joint, Femoral 
Surface with Autologous Tissue Substitute, 
Open Approach 
0SRS0J9 Replacement of Left Hip Joint, Femoral 
Surface with Synthetic Substitute, Cemented, 
Open Approach 
0SRS0JA Replacement of Left Hip Joint, Femoral 
Surface with Synthetic Substitute, 
Uncemented, Open Approach 
0SRS0JZ Replacement of Left Hip Joint, Femoral 
Surface with Synthetic Substitute, Open 
Approach 
0SRS0KZ Replacement of Left Hip Joint, Femoral 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
0SRR Replacement of Right Hip Joint, Femoral 
Surface 
0SRR0 Replacement of Right Hip Joint, Femoral 
Surface, Open Approach 
0SRR019 Replacement of Right Hip Joint, Femoral 
Surface with Metal Synthetic Substitute, 
Cemented, Open Approach 
0SRR01A Replacement of Right Hip Joint, Femoral 
Surface with Metal Synthetic Substitute, 
Uncemented, Open Approach 
0SRR01Z Replacement of Right Hip Joint, Femoral 
Surface with Metal Synthetic Substitute, Open 
Approach 
0SRR039 Replacement of Right Hip Joint, Femoral 
Surface with Ceramic Synthetic Substitute, 
Cemented, Open Approach 
0SRR03A Replacement of Right Hip Joint, Femoral 
Surface with Ceramic Synthetic Substitute, 
Uncemented, Open Approach 
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0SRR03Z Replacement of Right Hip Joint, Femoral 
Surface with Ceramic Synthetic Substitute, 
Open Approach 
0SRR07Z Replacement of Right Hip Joint, Femoral 
Surface with Autologous Tissue Substitute, 
Open Approach 
0SRR0J9 Replacement of Right Hip Joint, Femoral 
Surface with Synthetic Substitute, Cemented, 
Open Approach 
0SRR0JA Replacement of Right Hip Joint, Femoral 
Surface with Synthetic Substitute, 
Uncemented, Open Approach 
0SRR0JZ Replacement of Right Hip Joint, Femoral 
Surface with Synthetic Substitute, Open 
Approach 
0SRR0KZ Replacement of Right Hip Joint, Femoral 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
0SRD Replacement of Left Knee Joint 
0SRD0 Replacement of Left Knee Joint, Open 
Approach 
0SRD069 Replacement of Left Knee Joint with 
Oxidized Zirconium on Polyethylene 
Synthetic Substitute, Cemented, Open 
Approach 
0SRD06A Replacement of Left Knee Joint with 
Oxidized Zirconium on Polyethylene 
Synthetic Substitute, Uncemented, Open 
Approach 
0SRD06Z Replacement of Left Knee Joint with 
Oxidized Zirconium on Polyethylene 
Synthetic Substitute, Open Approach 
0SRD07Z Replacement of Left Knee Joint with 
Autologous Tissue Substitute, Open 
Approach 
0SRD0J9 Replacement of Left Knee Joint with 
Synthetic Substitute, Cemented, Open 
Approach 
0SRD0JA Replacement of Left Knee Joint with 
Synthetic Substitute, Uncemented, Open 
Approach 
0SRD0JZ Replacement of Left Knee Joint with 
Synthetic Substitute, Open Approach 
0SRD0KZ Replacement of Left Knee Joint with 
Nonautologous Tissue Substitute, Open 
Approach) 
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0SRD0L9 Replacement of Left Knee Joint with 
Unicondylar Synthetic Substitute, Cemented, 
Open Approach 
 
0SRD0LA Replacement of Left Knee Joint with 
Unicondylar Synthetic Substitute, 
Uncemented, Open Approach 
 
0SRD0LZ Replacement of Left Knee Joint with 
Unicondylar Synthetic Substitute, Open 
Approach 
 
0SRC Replacement of Right Knee Joint 
0SRC0 Replacement of Right Knee Joint, Open 
Approach 
0SRC069 Replacement of Right Knee Joint with 
Oxidized Zirconium on Polyethylene 
Synthetic Substitute, Cemented, Open 
Approach 
0SRC06A Replacement of Right Knee Joint with 
Oxidized Zirconium on Polyethylene 
Synthetic Substitute, Uncemented, Open 
Approach 
0SRC06Z Replacement of Right Knee Joint with 
Oxidized Zirconium on Polyethylene 
Synthetic Substitute, Open Approach 
0SRC07Z Replacement of Right Knee Joint with 
Autologous Tissue Substitute, Open 
Approach 
0SRC0J9 Replacement of Right Knee Joint with 
Synthetic Substitute, Cemented, Open 
Approach 
0SRC0JA Replacement of Right Knee Joint with 
Synthetic Substitute, Uncemented, Open 
Approach 
0SRC0JZ Replacement of Right Knee Joint with 
Synthetic Substitute, Open Approach 
0SRC0KZ Replacement of Right Knee Joint with 
Nonautologous Tissue Substitute, Open 
Approach) 
0SRC0L9 Replacement of Right Knee Joint with 
Unicondylar Synthetic Substitute, Cemented, 
Open Approach 
0SRC0LA Replacement of Right Knee Joint with 
Unicondylar Synthetic Substitute, 
Uncemented, Open Approach 
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0SRC0LZ Replacement of Right Knee Joint with 
Unicondylar Synthetic Substitute, Open 
Approach 
0SRU Replacement of Left Knee Joint, Femoral 
Surface 
0SRU0 Replacement of Left Knee Joint, Femoral 
Surface, Open Approach 
0SRU07Z Replacement of Left Knee Joint, Femoral 
Surface with Autologous Tissue Substitute, 
Open Approach 
 
0SRU0J9 Replacement of Left Knee Joint, Femoral 
Surface with Synthetic Substitute, Cemented, 
Open Approach 
 
0SRU0JA Replacement of Left Knee Joint, Femoral 
Surface with Synthetic Substitute, 
Uncemented, Open Approach 
0SRU0JZ Replacement of Left Knee Joint, Femoral 
Surface with Synthetic Substitute, Open 
Approach 
0SRU0KZ Replacement of Left Knee Joint, Femoral 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
0SRT Replacement of Right Knee Joint, Femoral 
Surface 
0SRT0 Replacement of Right Knee Joint, Femoral 
Surface, Open Approach 
0SRT07Z Replacement of Right Knee Joint, Femoral 
Surface with Autologous Tissue Substitute, 
Open Approach 
0SRT0J9 Replacement of Right Knee Joint, Femoral 
Surface with Synthetic Substitute, Cemented, 
Open Approach 
0SRT0JA Replacement of Right Knee Joint, Femoral 
Surface with Synthetic Substitute, 
Uncemented, Open Approach 
0SRT0JZ Replacement of Right Knee Joint, Femoral 
Surface with Synthetic Substitute, Open 
Approach 
0SRT0KZ Replacement of Right Knee Joint, Femoral 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
0SRW Replacement of Left Knee Joint, Tibial 
Surface 
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0SRW0 Replacement of Left Knee Joint, Tibial 
Surface, Open Approach 
0SRW07Z  Replacement of Left Knee Joint, Tibial 
Surface with Autologous Tissue Substitute, 
Open Approach 
0SRW0J9 Replacement of Left Knee Joint, Tibial 
Surface with Synthetic Substitute, Cemented, 
Open Approach 
0SRW0JA Replacement of Left Knee Joint, Tibial 
Surface with Synthetic Substitute, 
Uncemented, Open Approach 
0SRW0JZ Replacement of Left Knee Joint, Tibial 
Surface with Synthetic Substitute, Open 
Approach 
0SRW0KZ  Replacement of Left Knee Joint, Tibial 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
0SRV Replacement of Right Knee Joint, Tibial 
Surface 
0SRV0 Replacement of Right Knee Joint, Tibial 
Surface, Open Approach 
0SRV07Z  Replacement of Right Knee Joint, Tibial 
Surface with Autologous Tissue Substitute, 
Open Approach 
0SRV0J9 Replacement of Right Knee Joint, Tibial 
Surface with Synthetic Substitute, Cemented, 
Open Approach 
0SRV0JA Replacement of Right Knee Joint, Tibial 
Surface with Synthetic Substitute, 
Uncemented, Open Approach 
0SRV0JZ Replacement of Right Knee Joint, Tibial 
Surface with Synthetic Substitute, Open 
Approach 
0SRV0KZ  Replacement of Right Knee Joint, Tibial 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
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